参考文献/References:
[1].胡盛寿,高润霖,刘力生,等. 《中国心血管病报告2018》概要[J]. 中国循环杂志,2019, 34(3):209-220.
[2].Libby P,Hansson GK. From focal lipid storage to systemic inflammation:JACC review topic of the week[J]. J Am Coll Cardiol,2019,74(12):1594-1607.
[3].Williams JW,Huang LH,Randolph GJ,et al. Cytokine circuits in cardiovascular disease[J]. Immunity,2019,50(4):941-954.
[4].Libby P,Buring JE,Badimon L,et al. Atherosclerosis[J]. Nat Rev Dis Primers,2019,5(1):56.
[5].Mora S,Wenger NK,Demicco DA,et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy:the Treating to New Targets(TNT) study[J]. Circulation,2012,125(16):1979-1987.
[6].LaRosa JC,Grundy SM,Waters DD,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J]. N Engl J Med,2005,352(14):1425-1435.
[7].Ridker PM,Everett BM,Thuren T,et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.
[8].Cochain C ,Vafadarnejad E ,Arampatzi P ,et al. Single-cell RNA-Seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis[J]. Circ Res,2018,122 (12):1661-1674.
[9].Fernandez DM ,Rahman AH ,Fernandez NF ,et al. Single-cell immune landscape of human atherosclerotic plaques[J]. Nat Med,2019,25 (10):1576-1588.
[10].Tabas I,Lichtman AH. Monocyte-macrophages and T cells in atherosclerosis[J]. Immunity,2017, 47(4):621-634.
[11].Robbins CS,Hilgendorf I,Weber GF,et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis[J]. Nat M ed,2013,19(9):1166-1172.
[12].Stoneman V,Braganza D,Figg N,et al. Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques[J]. Circ Res,2007,100(6):884-893.
[13].Kim K,Shim D,Lee JS,et al. Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models[J]. Circ Res,2018, 123(10):1127-1142.
[14].Voll RE,Herrmann M,Roth EA,et al. Immunosuppressive effects of apoptotic cells[J]. Nature, 1997,390(6658):350-351.
[15].Foks AC,Ran IA,Wasserman L,et al. T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis[J]. Arterioscler Thromb Vasc Biol,2013,33(11):2558-2565.
[16].Xu H,Jiang J ,Chen W ,et al. Vascular macrophages in atherosclerosis[J]. J Immunol Res,2019,2019:4354786.
[17].Frodermann V,van Puijvelde GH,Wierts L,et al. Oxidized low-density lipoprotein-induced apoptotic dendritic cells as a novel therapy for atherosclerosis[J]. J Immunol,2015,194(5):2208-2218.
[18].Hosseini H,Li Y,Kanellakis P,et al. Phosphatidylserine liposomes mimic apoptotic cells to attenuate atherosclerosis by expanding polyreactive IgM producing B1a lymphocytes[J]. Cardiovasc Res,2015,106 (3):443-452.
[19].Stewart CR,Stuart LM,Wilkinson K,et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer[J]. Nat Immunol,2010,11(2):155-161.
[20].St?ger JL,Gijbels MJ,van der Velden S,et al. Distribution of macrophage polarization markers in human atherosclerosis[J]. Atherosclerosis,2012,225(2):461-468.
[21].Chinetti-Gbaguidi G,Colin S,Staels B. Macrophage subsets in atherosclerosis[J]. Nat Rev Cardiol,2015,12(1):10-17.
[22].Winkels H,Ehinger E,Vassallo M,et al. Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry[J]. Circ Res,2015, 122(12):1675-1688.
[23].Zernecke A. Dendritic cells in atherosclerosis:evidence in mice and humans[J]. Arterioscler Thromb Vasc Biol,2015,35(4):763-770.
[24].Weber C,Meiler S,Doring Y,et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice[J]. J Clin Invest,2011,121(7):2898-2910.
[25].Choi JH,Cheong C,Dandamudi DB,et al. Flt3 signaling-dependent dendritic cells protect against atherosclerosis[J]. Immunity,2011,35(5):819-831.
[26].Misharin AV,Morales-Nebreda L,Reyfman PA,et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span[J]. J Exp Med,2017,214(8):2387-2404.
[27].Huang LH,Zinselmeyer BH,Chang CH,et al. Interleukin-17 drives interstitial entrapment of tissue lipoproteins in experimental psoriasis[J]. Cell Metab,2019,29(2):475-487.
[28].Bennett MR,Sinha S,Owens GK. Vascular smooth muscle cells in atherosclerosis[J]. Circ Res, 2016,118(4):692-702.
[29].Nus M,Mallat Z. Immune-mediated mechanisms of atherosclerosis and implications for the clinic[J]. Expert Rev Clin Immunol,2016,12(11):1217-1237.
[30].Libby P,Hansson GK. Inflammation and immunity in diseases of the arterial tree:players and layers[J]. Circ Res,2015,116(2):307-311.
[31].Ketelhuth DF,Hansson GK. Adaptive response of T and B cells in atherosclerosis[J]. Circ Res,2016,118(4):668-678.
[32].Schloss MJ,Swirski FK,Nahrendorf M. Modifiable cardiovascular risk,hematopoiesis,and innate immunity[J]. Circ Res,2020,126(9):1242-1259.
[33].Kovanen PT. Mast cells as potential accelerators of human atherosclerosis—from early to late lesions[J]. Int J Mol Sci,2019,20(18):4479.
[34].Winkels H,Ley K. Natural killer cells at ease:atherosclerosis is not affected by genetic depletion or hyperactivation of natural killer cells [J]. Circ Res,2018,122(1):6-7.
[35].VanderLaan PA,Reardon CA,Cabana VG,et al. Invariant natural killer T-cells and total CD1d restricted cells differentially influence lipid metabolism and atherosclerosis in low density receptor deficient mice[J]. Int J Mol Sci,2019,20(18):4566.
[36].Getz GS,Reardon CA. Natural killer T cells in atherosclerosis[J]. Nat Rev Cardiol,2017,14(5):304-314.
[37].Ridker PM,Everett BM,Pradhan A,et al. Low-dose methotrexate for the prevention of atherosclerotic events[J]. N Engl J Med,2019,380(8):752-762.
[38].Leuschner F,Dutta P,Gorbatov R,et al. Therapeutic siRNA silencing in inflammatory monocytes in mice[J]. Nat Biotechnol,2011,29(11):1005-1010.
[39].Tang J,Lobatto ME,Hassing L,et al. Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation[J]. Sci Adv,2015,1(3):e1400223.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(1):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(1):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(1):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(1):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(1):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(1):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[7]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[8]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(1):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[9]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[10]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(1):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]